Poster presented at WCLC 2022 describing the final analysis of RATIONALE-303, a Phase 3 trial comparing tislelizumab versus docetaxel in previously treated advanced NSCLC.
Poster presented at WCLC 2022 describing the results of a metastatic NSCLC cohort from the phase 1b AdvanTIG-105 trial, showing a promising ORR and acceptable safety profile.
Report on updates in the treatment of lung cancer presented at WCLC and ESMO 2021.
Report on updates in the treatment of lung cancer presented at ASCO 2021.
Dr Benjamin Besse discusses targeting other components of immune checkpoint including TIGIT, TIM-3 and OX40 in immunotherapy combinations.